Nutriband, Inc. NTRB 深 沪
已收盘 12-19 16:00:00 美东时间
4.56
+0.030
+0.66%
华盛通- 最 高5.4532
- 今 开4.53
- 成交量 2.94万股
- 最 低 4.35
- 昨 收 4.53
- 总市值 3576.73万
- 52周最高 11.78
- 市盈率 静 --
- 换手率 0.37%
- 52周最低 3.76
- 委 比 18.97%
- 总股本 784.37万
- 历史最高 12.32
- 量 比 1.42
- 振 幅 24.35%
- 历史最低 0.00
- 每 手 1
- 风险率 1.27%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Nutriband and Kindeva Complete Commercial Manufacturing Process Scale-up for Aversa™ Fentanyl Abuse Deterrent Fentanyl Patch
Nutriband and Kindeva have successfully scaled up commercial manufacturing for Aversa™ Fentanyl, a pioneering abuse-deterrent fentanyl patch. This development marks a significant milestone toward submitting an Investigational New Drug (IND) application and initiating clinical studies to assess human abuse liability. The collaboration aims to provide a safer alternative for pain management, targeting both the US and global markets.
06-18 11:00
Nutriband Announces U.S. Patent Issued for Its Transdermal Abuse Deterrent Technology
Nutriband Inc. announced the issuance of a U.S. patent for its AVERSA™ abuse deterrent transdermal technology, expanding intellectual property coverage in the U.S. The technology aims to prevent drug abuse, diversion, and misuse through transdermal patches. Nutriband's lead product, Aversa™ Fentanyl, has the potential to become the first abuse deterrent pain patch, with estimated annual sales reaching $80 million to $200 million.
06-09 11:30
Nutriband Inc. to present at the 2025 Noble Capital Markets Virtual Equity Conference
<p>Nutriband Inc. announces that CEO Gareth Sheridan will present at Noble Capital Markets’ virtual conference on June 5th, 4PM EST. The presentation includes a Q&A session and 1x1 investor meetings. A webcast will be available on the company’s website and Channelchek for 90 days.</p>
06-03 12:00
Nutriband Inc. Quarterly Report Highlights Record Revenue for Q1, 2025 up 63% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl
Orlando, FL – Nutriband Inc. reported Q1 2025 revenue of $667K, up 63% YOY, driven by expansion of kinesiology tape through its Pocono Pharma subsidiary, now available at major retailers. The company advanced development of AVERSA Fentanyl, an abuse-deterrent opioid patch, through a partnership with Kindeva Drug Delivery, targeting peak US sales of $80M-$200M. Nutriband focuses on innovative transdermal pharmaceuticals, with AVERSA™ technology at its core.
06-02 12:00
莫德纳盘中异动 大幅拉升5.01%
北京时间2025年01月24日02时44分，莫德纳（MRNA.us）股票出现异动，股价快速上涨5.01%。截至发稿，该股报40.43美元/股，成交量577.952万股，换手率1.50%，振幅8.88%。 最近的财报数据显示，该股实现营业收入18.62亿美元，净利润13.00百万美元，每股收益0.03美元，毛利12.96亿美元，市盈率-6.95倍。 机构评级方面，在所有28家参与评级的机构中，29%的券商给予买入建议，57%的券商给予持有建议，14%的券商给予卖出建议。 莫德纳股票所在的生物技术行业中，整体涨幅为1.06%。其相关个股中，Dogwood Therapeutics, Inc.、Nu...
01-24 02:44
Corcept医疗盘中异动 下午盘快速上涨5.01%报61.99美元
北京时间2025年01月24日02时38分，Corcept医疗（CORT.us）股票出现波动，股价快速上涨5.01%。截至发稿，该股报61.99美元/股，成交量31.4609万股，换手率0.30%，振幅6.10%。 最近的财报数据显示，该股实现营业收入1.83亿美元，净利润46.69百万美元，每股收益0.45美元，毛利1.80亿美元，市盈率49.00倍。 机构评级方面，目前暂无机构对该股做出“买入、持有、卖出”建议。 Corcept医疗股票所在的生物技术行业中，整体涨幅为1.02%。其相关个股中，Dogwood Therapeutics, Inc.、Nutriband Inc C/Wts (T...
01-24 02:38
Microsoft, Intel And 3 Stocks To Watch Heading Into Tuesday
With U.S. stock futures trading mixed this morning on Tuesday, some of the stoc...
2024-09-17 14:15
